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Background. High circulating vascular endothelial growth factor (VEGF) levels tend to reﬂect tumor aggressiveness for being
associated with tumor progression and prognosis. Measurement of soluble VEGF receptor-1 (sVEGFR-1) may improve diagnostic
power of VEGF assay. Methods. This study investigated regulation of plasma VEGF by sVEGFR-1 in 82 patients with head and neck
squamous cell carcinoma compared with 32 healthy subjects to obtain information for assay characterization. Results.N o r m a l i t y
or abnormality of VEGF/sVEGFR-1secretion patterns was rated into ﬁve diagnostic levels from deﬁnitely abnormal (likelihood
ratios) (LRs = 4–∞) to deﬁnitely normal (LRs = 0–0.17). Because of ineﬀective VEGF regulation, high grade tumor had a greater
chance (62.5%) than low grade tumor (20%) in expressing a deﬁnitely abnormal pattern and a lower chance to express the normal
pattern (P = 0.007). VEGF alone had much lower diagnostic power in diﬀerentiating between normal (LRs = 0.3–0.9) and
abnormal secretion patterns (LRs = 2.2–2.4). Conclusions. VEGF dysregulation is suggestive of tumor aggressiveness for causing
persistent plasma VEGF elevation. sVEGFR-1 improves diagnostic power of VEGF assay particularly in identifying subset of low
grade tumor with underlying aggressive disease and ruling out aggressiveness in subset of high grade tumor.
1.Introduction
Head and neck squamous cell carcinoma (HNSCC) rep-
resents an aggressive epithelial malignancy. Most patients,
60−80%, are present with locally advanced disease at diag-
nosis[1].Distantmetastasisatthetimeofpresentationisless
common [2]. Metastasis to neck nodes is the most important
prognostic factor, and advanced clinical stage is frequently
linked to poor survival [3]. The tumor-node-metastasis
(TNM) staging provides an anatomical roadmap for tumor
site, size, and lymphatic involvement. Prognostic indicators
derived from the TNM system are usually insuﬃcient in
explaining the disease aggressiveness for HNSCC. Patients
with positive nodes may show diﬀerent survival proﬁles or
patients with negative nodes may be at risk of local relapse
[4]. Biomarkers capable of identifying patients with bio-
logically aggressive neoplasm would provide much-needed
information for improving treatment accuracy and eﬃcacy.
Angiogenesis is crucial for tumor growth, invasion, and
metastasis [5]. Vascular endothelial growth factor (VEGF), a
major regulator of angiogenesis and vascular permeability,
plays a key role in pathogenesis of HNSCC [6, 7]. Up to
90% of HNSCCs express VEGF and its receptors, VEGFR-
1–3 [6, 7]. Multiple studies on HNSCC demonstrated the
association of VEGF with tumor progression [8, 9], lymph
node metastasis [10, 11], and patient survival [6]. VEGF is
not only an independent prognostic indicator for HNSCC
[6] but also a potential target for anti-VEGF therapy [7].
Generally, tissue VEGF expression is a measure for tumor
angiogenicactivitybuttissuemeasurementhascertaindisad-
vantage for being invasive and not lending itself for dynamic
assessment of the angiogenic process. Detection of VEGF
in blood circulation of cancer patient oﬀers an alternative
means for measurement. Blood sampling is noninvasive and
can be performed at repeated intervals. In fact, shedding of
tumor-derived VEGF into systemic blood serves to recruit2 Journal of Oncology
bone marrow myeloid cells to provide additional angiogenic
factors to the tumor organ for growth and progression [12].
Extensive studies in several tumor types including head and
neck cancer [13–16], nonsmall cell lung cancer [17, 18],
l i v e rc a n c e r[ 19], renal cancer [17], colorectal cancer [17],
and ovarian cancer [20] revealed the correlation of elevated
circulating VEGF with tumor tissue expression [14, 17],
increased microvessel density [14], disease aggressiveness
including lymph node metastasis, advanced clinical stage
[14, 15], distant metastasis [16], and poor prognosis [13,
15, 17–20]. Despite these promising ﬁndings, circulating
VEGF assay is less well characterized for its sensitivity and
speciﬁcity in identifying patient with aggressive tumor. High
false-positive and negative ﬁndings are documented in many
reports [16, 21, 22]. An understanding of VEGF regulation
in the systemic blood may help assay optimization and data
interpretation.
VEGFrepresentstheangiogenicswitchwhichmayconfer
a metastatic potential to tumor even at the early stage of
growth. Further tumor progression is controlled by the
balance between positive and negative regulators of angio-
genesis [5]. Availability of active VEGF is regulated by its
soluble receptor-1 (sVEGFR-1) via ligand trapping [23]. In
physiologic context (e.g., exercise), sVEGFR-1 is upregulated
in responding to the rise in VEGF during exercise and is
responsible for normalizing the VEGF level to baseline [24].
In pathophysiologic context (e.g., cancer), sVEGFR-1 is fre-
quently coexpressed with VEGF [25–27]. Experimental and
clinical data are suggestive of the possible role of sVEGFR-1
in inhibiting VEGF-induced tumor angiogenesis and tumor
growth [25–28]. sVEGFR-1 level in excess of VEGF level is
an indicator of good prognosis [25–27]. On this basis, we
hypothesized that the relative VEGF and sVEGFR-1 levels
might be an important factor in determining the progression
of tumor from a less aggressive to a more aggressive stage.
In this study, we conducted a cross-sectional study of cases
and controls to analyze plasma VEGF/sVEGFR-1 secretion
proﬁles to understand how plasma VEGF was regulated in
patients with HNSCC compared with normal controls. The
studyvariablesincludedTNMstage,Tcategory,nodalstatus,
and tumor grade.
2.MaterialsandMethods
2.1. Study Population. The study population consisted of
82 patients with HNSCC and 32 healthy controls. Newly
diagnosed patients at the Department of Otolaryngology,
Ramathibodi Hospital were consecutively recruited during
June 2006 to May 2009. Patients with distant metastases,
lymph node metastases from unknown primaries were
excluded. Tumor staging was classiﬁed according to the
TNM system established by the American Joint Committee
on Cancer. The healthy volunteers, who had no history of
a known neoplasm and no clinical evidence of vascular,
metabolic and inﬂammatory diseases, were recruited among
hospital staﬀ and graduate students. Demographic data
of the study population are presented in Table 1.T h e
study protocol was approved by Ramathibodi Hospital
Table 1: Characteristics of the study population.
Characteristic Patient
(n = 82)
Normal
(n = 32)
Age, y
Mean (range) 58.4 (16–83) 31.7 (22–51)
Sex, n (%)
Male 64 (79) 7 (22)
Female 17 (21) 25 (78)
Primary site, n (%)
Nasopharynx 17 (20.7)
Oral cavity 23 (28)
Oropharynx 12 (14.6)
Hypopharynx 15 (18.3)
Larynx 15 (18.3)
Ts t a g e ,n (%)
T1-2 29 (35.4)
T3-4 53 (64.6)
Node status, n (%)
Negative 40 (48.8)
Positive 42 (51.2)
TNM stage, n (%)
I-II 18 (22.)
III-IV 64 (78)
Histological grade, n (%)
Well diﬀerentiated (G1) 31 (37.8)
Moderately diﬀerentiated (G2) 19 (23.2)
Poorly diﬀerentiated (G3) 22 (26.8)
Undiﬀerentiated (G4) 10 (12.2)
Ethics Committee. Patients and healthy subjects signed the
informed consents to participate in the study.
2.2. Plasma Collection and Assay. Six mL of peripheral blood
was collected into a tube with EDTA anticoagulant and
placed in an iced bucket. The blood samples from patients
were taken before treatment. Plasma was prepared within 1
hourofbloodcollectionbycentrifugationat4◦Catthespeed
of 1000g for 15 minutes. The plasma sample was aliquoted
a n ds t o r e da t−25◦C until assay.
Concentrations of VEGF and sVEGFR-1 were measured
using two commercially available ELISA kits designed to
measure VEGF121,V E G F 165, and sVEGFR-1 (Quantikine,
R&D Systems, Abingdon, UK). The VEGF assay kit (DVE00)
was reported to measure only unbound VEGF while the
sVEGFR-1 assay (DVR100) was reported to measure total
sVEGFR-1 [24, 29]. According to the manufacturer, the
minimum detectableconcentrationsforVEGF andsVEGFR-
1w e r e<9 and 5.01pg/mL, respectively.
2.3. Statistical Analysis. Comparisons of continuous data
wereperformedbytheMann-Whitneytestandofcategorical
data by χ2 test or Fisher exact test. All statistical tests were 2-
tailed, and P<0.05 was considered statistically signiﬁcant.Journal of Oncology 3
3. Results
3.1. Study Population Characteristics. This study enrolled
patients with SCC in the nasopharynx (20.7%), oral cavity
(28%), oropharynx (14.6%), hypopharynx (18.3%), and
larynx (18.3%). Regarding TNM stage, 64 out of 82 patients
(78%) had stage III and IV diseases. The averaged age
of patients (58.4 years) was higher than controls (31.7
years) (Table 1). The median VEGF and sVEGFR-1 levels
were also higher (P ≤ 0.03) (Table 2). The recruitment
of younger and more female healthy subjects as controls
(M/F = 7/25) was a point of concern. Regarding previous
publications,nosigniﬁcantassociationofVEGFwithageand
sex was reported in many studies [14, 20, 22]. In addition,
equilibrium distribution of VEGF/sVEGFR-1(VR) secretion
proﬁles observed for this control group was similar to that
of another control study by a group from our institute
(n = 99, age (SD) = 49.3 (0.4) years, M/F = 60/39, personal
communication).
3.2. VEGF/sVEGFR-1 (VR) Secretion Proﬁles. Physiologic
angiogenesis is a tightly regulated process to maintain the
dynamic equilibrium between proangiogenic and antian-
giogenic factors [23]. Malignant tumor utilizes the same
angiogenic process for progression by upregulating the
proangiogenic factors and downregulating the angiogenic
inhibitors [5, 23]. Therefore, median concentrations of
VEGF (V) and sVEGFR-1(R) of the control group were
used as cut-oﬀ for high (H) and low (L) secretion levels.
Four patterns of VR secretion proﬁles were deﬁned as VHRL,
VHRH,V LRH,a n dV LRL to project the rise of VEGF level
(VHRL) followed by the upregulation of sVEGFR-1 (VHRH),
then the suppression of VEGF by sVEGFR-1 (VLRH)a n d
eventually both factors returning to baseline (VLRL). A
balanced distribution of VR secretion proﬁles was observed
in controls (Table 2). Subjects with elevated VEGF (28%),
that is VHRL proﬁle, were in balance with subjects (25%)
with a VHRH proﬁle. Normalization of VEGF level was
evidenced by the shift of VHRH (25%) to VLRH (31%)
and eventually to VLRL (16%). This was in contrast to the
observation in patients from which the distribution was
skewed toward VHRH proﬁle (54.9%).
3.3. VEGF Regulation Regarding Tumor Stage and Grade. It
has been demonstrated by cell culture study that tumor-
derived VEGF is able to induce the expression of sVEGFR-
1[ 30]. Upregulation of sVEGFR-1 by VEGF represents
a negative feedback mechanism in regulating the level of
VEGF as shown by the exercise study [24]. In this study,
sVEGFR-1 upregulation was demonstrated by the shift of
VHRL to VHRH proﬁle and VEGF suppression by the shift
of VHRH to VLRH proﬁle. In relation to controls, marked
shifts from VHRL to VHRH were recognized in patients with
less aggressive disease stages including stage I, II; T1,2;N −
and low-grade tumor (G1,2) but the magnitudes of shifts
were not large enough to reach signiﬁcant levels (P ≥ 0.11)
(Table 3). However, the regulative capability of sVEGFR-1in
normalizing VEGF levels in these patients was similar to
that of healthy controls (P ≥ 0.38) (Table 3). In contrast,
Table 2: Plasma VEGF and sVEGFR-1 levels and VR secretion
proﬁle.
Variable Normal
(n = 32) HNSCC (n = 82) P
VEGF, pg/mL
Mean (SD) 41.7 (50.1) 71.1 (133.7)
Median (IQR) 22.8 (14.5–38.1) 29.4 (19.3–73.9) 0.03
sVEGFR-1, pg/mL
Mean (SD) 35.3 (30.1) 45.1 (27.7)
Median (IQR) 27.9 (19.5–34) 37.2 (29.8–54.3) 0.0001
VR secretion proﬁle 0.03
VHRL, n (%) 9 (28.1) 11 (13.6)
VHRH, n (%) 8 (25) 45 (54.9)
VLRH, n (%) 10 (31.3) 17 (20.7)
VLRL, n (%) 5 (15.6) 9 (11)
signiﬁcant sVEGFR-1 upregulation could be conﬁrmed in
patients with more aggressive disease stages (P ≤ 0.009),
buttheupregulatedsVEGFR-1failedtosuppressVEGFlevels
in these patients with stage III, IV; T3,4; N+ and high grade
tumor (G3,4)( P ≤ 0.02).
Since TNM variables and tumor grade were related
to VEGF regulation it might be more relevant to analyze
the eﬀect of VEGF regulation in association with stepwise
increase in combined tumor grade and stage to obtain an
alternative point of view of VEGF regulation during the
transition of tumor from low grade at an early state to
high grade at the advanced stage. In this part, VR secretion
proﬁles along with absolute concentrations of VEGF and
sVEGFR-1 were determined for healthy controls, patients
subgroups categorized according to the above elaboration
(Table 4). Interestingly, median sVEGFR-1 levels in patients
were signiﬁcantly higher than that of controls for all steps
of disease transition (P ≤ 0.04). But the elevated sVEGFR-
1 could normalize the VEGF levels only in low-grade tumor
(G1,2) regardless the tumor stage. This statement was based
on the observation of insigniﬁcant increases in VEGF levels
(P ≥ 0.2) along with the balanced distributions of VR
secretion proﬁles which were comparable to that of controls
(P = 0.33). In high-grade tumor (G3,4), mostly presented
at advanced stage (93.8%), the elevated sVEGFR-1 failed to
suppress the VEGF levels as indicated by marked increases in
VEGF levels (P ≤ 0.002). The distribution of VR secretion
proﬁles was skewed toward VHRH and diﬀered signiﬁcantly
from that of controls (P = 0.002).
3.4.NormalityandAbnormalityofVEGF/sVEGFR-1Secretion
Patterns. For the purpose of assay characterization, the
VEGF/sVEGFR-1 secretion patterns for theentire study pop-
ulation were grouped into eight categories. Firstly, four levels
of VEGF concentrations were graded: above 80 percentile
rank, 84.5pg/mL, as very high (VHH); between 60 and 80
percentile ranks, 32.5–84.5pg/mL, as high (VH); between 40
and 60 percentile ranks, 23.2–32.5pg/mL, as intermediate
(VI); below 40 percentile rank, 23.2pg/mL, as low (VL).4 Journal of Oncology
Table 3: sVEGFR-1 upregulation and VEGF suppression in association with clinicopathological parameters.
Parameter
sVEGFR-1 upregulation, n (%) VEGF suppression, n (%)
VHRL VHRH P∗ VHRH VLRH P∗
Control 9 (52.9) 8 (47.1) — 8 (44.4) 10 (55.6) —
TNM stage
I, II 3 (33.3) 6 (66.7) 0.43 6 (50) 6 (50) 1
III, IV 8 (17) 39 (83) 0.009 39 (78) 11 (22) 0.02
Ts t a g e
T1,2 4 (26.7) 11 (73.3) 0.17 11 (57.9) 8 (42.1) 0.52
T3,4 7 (17) 34 (83) 0.009 34 (79) 9 (21) 0.01
Nodal status
N− 6 (26) 17 (74) 0.29 17 (58.6) 12 (41.4) 0.38
N+ 5 (15.2) 28 (84.8) 0.008 28 (84.9) 5 (15.1) 0.003
Tumor grade
G1,2 7 (25.9) 20 (74.1) 0.11 20 (58.8) 14 (41.2) 0.39
G3,4 4 (14) 25 (86) 0.007 25 (89.3) 3 (10.7) 0.002
∗Comparison between tumor and normal controls.
Table 4: VR secretion proﬁle and VEGF and sVEGFR-1 concentrations in correlation with stepwise increase in combined tumor grade and
stage.
Tumor grade
and stage
VR secretion proﬁle, n (%) VEGF, pg/mL sVEGFR-1, pg/mL
VHRL VHRH VLRH VLRL Median (range) P∗ Median
(range) P∗
Normal
control 9 8 10 5 22.9 — 27.86 —
(n = 32) (28.1) (25) (31.3) (15.6) (7.1–228.7) (10.4–147.4)
G1,2 T1,2 N− 2 5 6 3 20.6 0.46 32.74 0.04
(n = 16) (12.5) (31.3) (37.5) (18.8) (10.2–124.6) (18.1–194)
G1,2 T3,4 N− 1 6 5 2 21.6 0.30 43.7 0.004
(n = 14) (7.1) (42.9) (35.7) (14.3) (1.3–168) (17.3–171)
G1,2 T1–4 N+ 4 9 3 4 25.6 0.20 33.32 0.03
(n = 20) (20) (45) (15) (20) (13.4–1121.9) (21.2–78)
G3,4 T2–4 N− 3 6 1 0 91.5 0.002 35.79 0.04
(n = 10) (30) (60) (10) (0) (21.3–271.6) (15.5–54.1)
G3,4 T3-4 N+ 1 19 2 0 65.4 0.0008 58.84 <.0001
(n = 22) (4.5) (86.4) (9.1) (0) (17.5–258.5) (28.8–92.4)
∗Comparison between patients and normal controls.
Secondly, the associated sVEGFR-1 levels were divided as
high (RH) and low (RL) using the median concentration of
34.5pg/mL as a cutoﬀ. VEGF/sVEGFR-1 secretion patterns
for the healthy subjects and patients with low-grade and
high-grade tumors were classiﬁed accordingly (Table 5).
The degree of abnormality/normality for each of the
eight VEGF/sVEGFR-1 secretion patterns was rated based
on the magnitude of its likelihood ratio (LR) which is
a ratio of two proportions: the subset of cancer patients
with a particular secretion pattern divided by the subset of
normal subjects with the same pattern. A VEGF/sVEGFR-
1 secretion pattern was graded as abnormal for a much
greater likelihood of being observed in cancer patients than
in healthy controls and the reverse was true for a pattern
rated as normal. This study in accordance with the standard
diagnostic rating scales [31] rated the VEGF/sVEGFR-1
secretion patterns with LRs 4–∞ as deﬁnitely abnormal;
2.56 as probably abnormal; 0.8–1.66 as possibly abnormal;
0.3–0.59 as probably normal; 0–0.17 as deﬁnitely normal
(Table 6). Patterns with intermediate to very high levels of
VEGF in association with high sVEGFR-1 level represented
abnormal secretion patterns for their high LRs ≥ 4. But
patterns with low sVEGFR-1 levels no matter how high
the VEGF levels were tended to tilt towards normality with
decreasing LRs from 1 to 0. Patients with high-grade tumor
hadagreaterchance(62.5%)toexpressadeﬁnitelyabnormal
VEGF/sVEGFR-1 secretion pattern than low-grade tumor
(20%)andalowerchance(37.6%versus72%)tobeobserved
with normal secretion pattern (P = 0.007). However,
without taking levels of sVEGFR-1 into consideration, VEGFJournal of Oncology 5
Table 5: VEGF/sVEGFR-1 and VEGF secretion patterns in normal controls and patients with low-grade and high-grade tumors.
VEGF sVEGFR-1 Normal controls, n (%) Low-grade tumor, n High-grade tumor, n
(%)
pg/mL pg/mL (n = 32) (%) (n = 50) (n = 32)
Very high, VHH >
84.5
High, RH ≥ 34.5 0 (0) 3 (6) 7 (21.9)
Low, RL < 34.5 5 (15.6) 3 (6) 5 (15.6)
Total 5 (15.6) 6 (12) 12 (37.5)
High, VH 32.5–84.5 High, RH ≥ 34.5 1 (3.1) 4 (8) 9 (28.1)
Low, RL < 34.5 4 (12.5) 3 (6) 2 (6.3)
Total 5 (15.6) 7 (14) 11 (34.4)
Intermediate, VI
23.2–32.5
High, RH ≥ 34.5 1 (3.1) 7 (14) 4 (12.5)
Low, RL < 34.5 4 (12.5) 6 (12) 0 (0)
Total 5 (15.6) 13 (26) 4 (12.5)
Low, VL < 23.2 High, RH ≥ 34.5 5 (15.6) 13 (26) 3 (9.4)
Low, RL < 34.5 12 (37.5) 11 (22) 2 (6.3)
Total 17 (53.1) 24 (48) 5 (15.6)
Table 6: Likelihood ratios (LR), degree of normality/abnormality for VEGF/sVEGFR-1 (V/R), and VEGF (V) secretion patterns.
Test result
Low-grade tumor (n = 50) High-grade tumor (n = 32)
V/R, n (%) LR V, n (%) LR V/R, n (%) LR V, n (%) LR
Deﬁnitely VHHRH,3( 6 ) ∞ —— V HHRH, 7 (21.9) ∞ ——
abnormal VIRH, 7 (14) 4.47 VHRH, 9 (28.1) 9
VIRH, 4 (12.5) 4
Probably VHRH, 4 ( 8 ) 2 . 5 6 — ——— V HH, 12 (37.5) 2.42
abnormal VH, 11 (34.4) 2.2
Possibly VLRH, 13 (26) 1.66 VHH, 6 (12) 0.8 VHHRL, 5 (15.6) 1 VI, 4 (12.5) 0.8
abnormal VIRL, 6 (12) 0.96 VH, 7 (14) 0.9
VI, 13 (26) 1.66
VL, 24 (48) 0.9
Probably VHHRL,3( 6 ) 0 . 3 8 — — V HRL, 2 (6.3) 0.5 VL, 5 (15.6) 0.3
normal VHRL,3( 6 ) 0 . 4 8 V LRH, 3 (9.4) 0.6
VLRL, 11 (22) 0.59
Deﬁnitely — — — — VIRL,0( 0 ) 0 — —
normal VLRL, 2 (6.3) 0.17
alone had much lower diagnostic power in diﬀerentiating
normal (LRs = 0.3–0.9) from abnormal secretion patterns
(LRs = 2.2–2.4).
4. Discussion
Using high circulating VEGF levels as an index for disease
aggressiveness is based on its association with tumor pro-
gressionandprognosis[13–20]. However, high false-positive
andnegativerateswerethecauseofconcernforassayvalidity
[16, 21, 22]. This deﬁciency might be discerned on how we
deﬁned the disease aggressiveness. Advanced clinical stage is
generally considered as aggressive disease stage by the TNM
criteria. Our study on VEGF regulation by sVEGFR-1 in
correlation with stepwise increases in combined tumor grade
and stage starting from low grade at an early stage to high
grade at the advanced stage revealed that the upregulated
sVEGFR-1 in high-grade tumor which mostly presented at
advanced stage failed to normalize the VEGF levels leading
to persistent VEGF elevation. While the regulative capability
of sVEGFR-1 for low-grade tumor in all stages remained
eﬀective and was capable of normalizing the VEGF levels
in most patients. Based on the observation in our series on
HNSCC, combined high grade and advanced stage rather
than the advanced stage alone was the signiﬁcant feature for
disease aggressiveness evidenced by VEGF dysregulation.
Our ﬁndings were in line with several studies on ex-
perimental tumor models and human tumor specimens.
Experimentally, the association of tumor grade and angio-
genesis had been demonstrated by a mouse prostate cancer
model [32]. Expression of VEGF in tissue and serum was
observed in poorly diﬀerentiated tumor but not in well- and
moderately diﬀerentiated tumors. In a human brain tumor
model, VEGF has been suggested to be a protagonist in6 Journal of Oncology
controlling the transition from low-grade glioma to highly
vascularized malignant glioma [33]. A high VEGF-to-
sVEGFR-1 ratio indicating a VEGF-dominant state was
determined for malignant glioblastomas in contrast to the
lower ratio, which signiﬁed an sVEGFR-1-dominant state,
for diﬀuse astrocytomas [34]. The association of VEGF
expression with tumor aggressiveness was also demonstrated
in study of a HNSCC cell line transfected with VEGF cDNA
[35]. The cell line used for the study was characterized as
a low VEGF expressor, having a nonaggressive phenotype
for being a well-diﬀerentiated and slow growing tumor in
vivo. VEGF transfection was suﬃcient to induce tumor
aggressiveness characterized by rapid tumor growth and
stromal invasion.
In assaywise, the VEGF/sVEGFR-1 secretion patterns
deﬁned for the entire study population were rated for their
degree of normality or abnormality according to their LRs
describing the chance of a particular secretion pattern being
observed in cancer patients in contrast to healthy controls.
Secretion patterns designating high levels of VEGF and
sVEGFR-1 were regarded as abnormal for their LRs of ≥4
and were suggestive of VEGF dysregulation as sVEGFR-1
failedtosuppress VEGF levels. As expected, more high-grade
tumors (62.5%) than the low grade (20%) were observed
to express a deﬁnitely abnormal VEGF/sVEGFR-1 pattern.
Interestingly, patterns with low sVEGFR-1 levels no matter
how high the VEGF levels were had low LRs ≤ 1 to signify
a normal pattern. Without taking the levels of sVEGFR-1
into consideration, VEGF alone had much lower diagnostic
power in diﬀerentiating between normal (LRs = 0.3–0.9) and
abnormal secretion patterns (LRs = 2.2–2.4). Measurement
of sVEGFR-1 could enhance the diagnostic power of VEGF
assay particularly in ruling in and ruling out the aggressive
disease stage under high VEGF concentrations. High levels
of both VEGF/sVEGFR-1 could help identify subset of low-
grade tumor with underlying aggressive disease state, while
high VEGF levels with low receptor concentrations, which
was a normal secretion pattern, observed in a subset of high-
grade tumor might indicate the nonaggressive disease state.
The results from this study suggest that plasma VEGF
and sVEGFR-1 could serve as useful biomarkers to help
strengthening the prognostic power of the pretreatment
circulating VEGF assay used by many investigators [13,
15, 17–20]. Of special interest is the management of
tumor hypoxia, an important characteristic of the aggressive
malignant phenotype observed in HNSCC [36]. Hypoxia is
known to be a condition that activates the expression of
VEGF and sVEGFR-1 [23, 30]. The high VEGF/sVEGFR-1
secretion pattern might reﬂect tumor hypoxia and indicate
the justiﬁcation of incorporating the VEGF targeting agent
such as bevacizumab into the chemoradiation regime with
the expectation that VEGF inhibition might induce vascular
normalization which would lead to improved tumor oxy-
genation and thereby sensitizing tumor to radiation [37].
5. Conclusion
High circulating VEGF levels tend to reﬂect tumor aggres-
siveness for being associated with advanced stage and poor
prognosis. For HNSCC, high-grade tumor with advanced
stage was aggressive compared to low-grade tumor at all
stages because of its ineﬀective VEGF regulation by sVEGFR-
1 leading to persistent VEGF elevation. Measurement of
sVEGFR-1 helps improve the diagnostic power of the VEGF
assay particularly in ruling in and ruling out the aggressive
disease state under high VEGF concentrations. VEGF and
sVEGFR-1 would serve as useful biomarkers for better
prediction of prognosis than VEGF alone and provide
information for management of tumor hypoxia.
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